CoChat

Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison

Open access

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patients with acne. METHODS: In this multicenter, randomized, investigator-blinded, vehicle-controlled study, subjects with moderate or severe facial acne (Investigator's Global Assessment [IGA] score 3 or 4; ≥ 25 inflammatory lesions; ten or more atrophic acne scars) applied A0.3/BPO2.5 or vehicle daily per half face for 24 weeks. Subjects with acne requiring systemic treatment were excluded. Assessments included investigator atrophic acne scar count, Scar Global Assessment (SGA), acne lesion count, IGA, skin roughness and skin texture, subject self-assessment of clinical acne-related scars and satisfaction questionnaire, tolerability, and safety. RESULTS: Included subjects (n = 67) had mainly moderate acne (92.5% IGA 3); mean scores at baseline were approximately 40 acne lesions and 12 scars per half face. By week 24, the change from baseline in total scar count was - 15.5% for A0.3/BPO2.5 versus + 14.4% for vehicle (approximately 30% difference), with a mean of 9.5 scars versus 13.3 per half face, respectively (p < 0.0001). For SGA at week 24, a total of 32.9% with A0.3/BPO2.5 versus 16.4% with vehicle (p < 0.01) were clear/almost clear. Inflammatory acne lesions decreased by 86.7% for A0.3/BPO2.5 versus 57.9% for vehicle (p < 0.0001), and 64.2 versus 19.4% of subjects, respectively, were IGA clear/almost clear (p < 0.0001) at week 24. Treatment-related AEs were reported by 20.9% for A0.3/BPO2.5 versus 9% for vehicle side, most commonly skin irritation (14.9 vs. 6%, respectively). CONCLUSIONS: Topical A0.3/BPO2.5 prevented and reduced atrophic scar formation. Scar count increased with vehicle (+ 14.4%) but decreased with A0.3/BPO2.5 (- 15.5%) over 24 weeks. TRIAL REGISTRY: ClinicalTrials.gov identifier NCT02735421.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40257-018-0352-y

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effect on scars demonstrated by a total atrophic scar count at week 24, b mean percentage change from baseline of total atrophic scar count by visit (ITT; N = 67), and c percentage of subjects with Scar Global Assessment clear/almost clear by visit (ITT; N = 67). A0.3/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gel, ITT intention to treat, LOCF last observation carried forward, PP per protocol
Fig. 1 Effect on scars demonstrated by a total atrophic scar count at week 24, b mean percentage change from baseline of total atrophic scar count by visit (ITT; N = 67), and c percentage of subjects with Scar Global Assessment clear/almost clear by visit (ITT; N = 67). A0.3/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gel, ITT intention to treat, LOCF last observation carried forward, PP per protocolCC BY-NC · PubMed Central
Fig. 2 Effect on lesions expressed as median percentage change from baseline in a total, b inflammatory, and c non-inflammatory lesion count (each result is for half a face) (intention-to-treat population; N =67). A0.3/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gel
Fig. 2 Effect on lesions expressed as median percentage change from baseline in a total, b inflammatory, and c non-inflammatory lesion count (each result is for half a face) (intention-to-treat population; N =67). A0.3/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gelCC BY-NC · PubMed Central
Fig. 3 Percentage of subjects clear/almost clear of acne lesions on Investigator Global Assessment (intention-to-treat population; N =67)
Fig. 3 Percentage of subjects clear/almost clear of acne lesions on Investigator Global Assessment (intention-to-treat population; N =67)CC BY-NC · PubMed Central
Fig. 4 Representative photographs of two subjects who applied adapalene 0.3%/benzoyl peroxide 2.5% gel on the right side of their face and vehicle on the left side. a An 18-year-old subject with Scar Global Assessment (SGA) scores of mild on both sides at baseline (scar count: eight scars A0.3/BPO2.5 vs. five vehicle) and, at week 24, mild SGA on the A0.3/BPO2.5 side (11 scars) and moderate SGA on the vehicle side (16 scars). b A 16-year-old subject with moderate SGA on both sides at baseline (scar count: 32 scars on each side) and moderate SGA on both sides at week 24 (27 scars A0.3/BPO2.5 side vs. 29 scars vehicle side)
Fig. 4 Representative photographs of two subjects who applied adapalene 0.3%/benzoyl peroxide 2.5% gel on the right side of their face and vehicle on the left side. a An 18-year-old subject with Scar Global Assessment (SGA) scores of mild on both sides at baseline (scar count: eight scars A0.3/BPO2.5 vs. five vehicle) and, at week 24, mild SGA on the A0.3/BPO2.5 side (11 scars) and moderate SGA on the vehicle side (16 scars). b A 16-year-old subject with moderate SGA on both sides at baseline (scar count: 32 scars on each side) and moderate SGA on both sides at week 24 (27 scars A0.3/BPO2.5 side vs. 29 scars vehicle side)CC BY-NC · PubMed Central
Fig. 5 Subject questionnaire. When looking at the left/right hand side of your face in the mirror right now, a “How many indents or holes do you see?” (b) “How visible are the indents or holes to you?” (intention-to-treat population). A03/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gel
Fig. 5 Subject questionnaire. When looking at the left/right hand side of your face in the mirror right now, a “How many indents or holes do you see?” (b) “How visible are the indents or holes to you?” (intention-to-treat population). A03/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gelCC BY-NC · PubMed Central
Fig. 6 Local tolerance stinging/burning score between baseline (N = 66) and week 24 (N =54) (all patients treated population). A03/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gel
Fig. 6 Local tolerance stinging/burning score between baseline (N = 66) and week 24 (N =54) (all patients treated population). A03/BPO2.5 adapalene 0.3%/benzoyl peroxide 2.5% gelCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 78

Metadata

Authors
Dréno, B., Bissonnette, R., Gagné-Henley, A., Barankin, B., Lynde, C., Kerrouche, N., & Tan, J.
Affiliations
  • Inserm (FR)
  • Innovaderm (Canada) (CA)
  • Lynde Centre for Dermatology (CA)
  • Galderma (France) (FR)
  • Western University (CA)
Corresponding author
Dréno, Brigitte
Venue
American Journal of Clinical Dermatology
Published
2018-03-16
Volume
19
Issue
2
Pages
275-286
ISSN
  • 1175-0561 (ISSN-L)
  • 1179-1888
OpenAlex
W2794146536
Cited by
69
References
31
Citations by year
2026: 6 · 2025: 9 · 2024: 11 · 2023: 9 · 2022: 10 · 2021: 4 · 2020: 7 · 2019: 7 · 2018: 4
FWCI
5.95
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
Galderma
Topics
  • Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
Keywords
atrophic acne scars, adapalene, benzoyl peroxide, topical acne treatment, facial acne, inflammatory acne lesions, skin texture, safety and tolerability, intraindividual comparison, acne, patient satisfaction, skin roughness
MeSH terms
Adapalene, Acne Vulgaris, Administration, Cutaneous, Adolescent, Adult, Atrophy, Benzoyl Peroxide, Cicatrix, Dermatologic Agents, Double-Blind Method, Drug Combinations, Face, Female, Gels, Humans, Male, Severity of Illness Index, Skin, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison. https://app.cochat.ai/papers/10.1007/s40257-018-0352-y
The paper
Dréno, B., Bissonnette, R., Gagné-Henley, A., Barankin, B., Lynde, C., Kerrouche, N., & Tan, J. (2018). Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-018-0352-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.